Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.

Mutations in KRAS drive PDAC. (A) Illustration depicting different stages of PDAC, in which tumors originating in the pancreas (stage 1) first extend to lymph nodes and bile ducts (stage 2), then ...

“Setidegrasib is the first drug in this KRAS degrader class targeting KRAS G12D in solid tumors,” lead investigator Wungki ...

The KRAS gene is responsible for producing a protein also called KRAS that’s involved in regulating the entrance of signaling molecules into the nucleus of a cell. Many of the nuclear signaling ...

Ensem Therapeutics highlights novel, potent, and selective oral pan-KRAS and WRN inhibitors with best-in-class potential at ...

Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial. This is an ASCO Meeting Abstract from ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...